Seagen’s cancer drug research and collaborations have focused on the development of antibody drug conjugates. By licensing rights to a preclinical Lava Therapeutics asset, Seagen gets a shot to develop a different kind of antibody therapy that could compete against approved products from Johnson & Johnson and Takeda Pharmaceutical.
Design Therapeutics raised $240 million in the biggest biotech IPO this week. One other rare disease drug developer went public along with two oncology biotechs as the IPO momentum continues.
In a recent interview, Esperion president and CEO, Sheldon Koenig talks about the reality of statin intolerance and his company’s expansion into new diseases
The company plans to start clinical development next year. Its focus is on bispecific antibodies - a form of cancer immunotherapy - that use gamma-delta "surveillance" T cells.
Lava Therapeutics nets 16 million euros in Series B round and plans to decide on clinical drug candidate in oncology this year.